1 week Ago By ABMN Staff
Westside Investment Management Inc. lifted its holdings in Johnson & Johnson ( NYSE:JNJ – Free Report ) by 13.3% in the fourth quarter, according to its most recent disclosure with the SEC.
The institutional investor owned 4,859 shares of the company’s stock after purchasing an additional 570 shares during the period. Westside Investment Management Inc.’s holdings in Johnson & Johnson were worth $703,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC grew its position in shares of Johnson & Johnson by 138.9% during the fourth quarter.
IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson in the third quarter worth approximately $31,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $35,000.
Mowery & Schoenfeld Wealth Management LLC increased its position in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the last quarter.
Finally, Activest Wealth Management purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.
22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220.
This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . 0.
16% of the stock is currently owned by company insiders. Johnson & Johnson Stock Performance Johnson & Johnson ( NYSE:JNJ – Get Free Report ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.
04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05.
Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%.
The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same period in the prior year, the company posted $2.
29 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis.
On average, sell-side analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current year. Johnson & Johnson Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th.
Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.
96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th.
Johnson & Johnson’s dividend payout ratio is presently 74.59%. Analyst Upgrades and Downgrades JNJ has been the topic of several recent analyst reports.
Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th.
Guggenheim increased their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th.
Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.
00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.
00 target price on shares of Johnson & Johnson in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $170.
06. Check Out Our Latest Stock Report on Johnson & Johnson Johnson & Johnson Profile ( Free Report ) Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. Further Reading Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter ..
